Biofrontera Inc./$BFRI
1D1W1MYTD1Y5YMAX
Capital at risk
About Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
- Ticker
- $BFRI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 89
- Headquarters
- Woburn, United States
- Website
- www.biofrontera-us.com
Biofrontera Inc. Metrics
BasicAdvanced
$15M
-
-$0.54
0.80
-
Price and volume
Market cap
$15M
Beta
0.8
52-week high
$1.66
52-week low
$0.55
Average daily volume
673K
Financial strength
Current ratio
1.18
Quick ratio
0.999
Long term debt to equity
1.181
Total debt to equity
1.26
Interest coverage (TTM)
-12.78%
Profitability
EBITDA (TTM)
-5.968
Gross margin (TTM)
79.25%
Net profit margin (TTM)
-13.78%
Operating margin (TTM)
-13.36%
Effective tax rate (TTM)
-0.46%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-17.45%
Return on equity (TTM)
-988.35%
Valuation
Price to revenue (TTM)
0.265
Price to book
2.48
Price to tangible book (TTM)
4.36
Price to free cash flow (TTM)
-1.544
Free cash flow yield (TTM)
-64.78%
Free cash flow per share (TTM)
-0.674
Growth
Revenue change (TTM)
17.83%
Earnings per share change (TTM)
-74.28%
3-year revenue growth (CAGR)
16.71%
3-year earnings per share growth (CAGR)
-68.68%
Biofrontera Inc. Financial Performance
Revenues and expenses
Biofrontera Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.